IL17A and neoplasm: Tumor necrosis factor alpha (TNF-α) and interleukin-17 (IL-17) are mainly affected by anti-PD-1/anti-PD-L1 therapies because they contribute to the expression of PD-L1 in both tumor and immune cells [85].